Thermo Fisher Scientific To Acquire CorEvitas, For $912.5M In Cash
Portfolio Pulse from Happy Mohamed
Thermo Fisher Scientific Inc. (NYSE:TMO) has announced its plans to acquire CorEvitas, LLC, a provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, for $912.5 million in cash. The acquisition is expected to be immediately accretive to Thermo Fisher's adjusted earnings per share. The transaction is expected to be completed by the end of 2023.
July 06, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Thermo Fisher's acquisition of CorEvitas is expected to be immediately accretive to its adjusted earnings per share. This could potentially boost Thermo Fisher's stock in the short term.
The acquisition of CorEvitas is expected to be immediately accretive to Thermo Fisher's adjusted earnings per share, which is a positive signal for investors. This could potentially lead to an increase in Thermo Fisher's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100